| Previous Close | 73.76 |
| Open | 73.70 |
| Bid | 73.10 x 500 |
| Ask | 74.88 x 100 |
| Day's Range | 73.19 - 74.42 |
| 52 Week Range | 63.76 - 88.85 |
| Volume | 8,943,242 |
| Avg. Volume | 8,651,084 |
| Market Cap | 97.21B |
| Beta | 0.96 |
| PE Ratio (TTM) | 7.86 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.82%) |
| Ex-Dividend Date | 2017-06-14 |
| 1y Target Est | N/A |
- Investor's Business Daily•6 hours ago
Gilead's HIV Drug Matches Glaxo Rival In Late-Stage Trials
Glaxo shares dipped near a two-week low after Gilead's HIV drug combination proved to be non-inferior in a late-stage trial.
- Motley Fool•7 hours ago
3 Things You Can Expect in Gilead Sciences' Q2 Update
Hint: The list doesn't include higher sales for its hepatitis C franchise.
- Barrons.com•8 hours ago
Gilead Sciences: There's Always Safety
Gielad Sciences (GILD) reported trial data for an HIV treatment this morning, and it wasn't the blockbuster many might have hoped it would be. That doesn't mean it's a total loss, either. BMO analysts ...
